Pune based Serum Institute, known to be the world’s largest vaccine manufacturer in terms of volume, has set a maximum price of $3 per dose for the COVID-19 vaccine for INDIA and LMICs LMICs are low and middle-income countries.
The Bill and Melinda Gates Foundation has decided to provide $150 million to GAVI. This amount would be used to support Serum in manufacturing potential vaccine candidates, including AstraZeneca from the UK and Novavax, a US biotech company.
Total 92 countries are getting benefited This maximum price is only for vaccines for the 92 countries under COVAX Alliance — Co-led by GAVI, WHO (world health organization) and CEPI (Coalition for Epidemic Preparedness Innovations, to make fast the development of the vaccine for COVID-19 and to ensure their fast and easy access.
The company this Friday made a partnership with GAVI and Bill & Melinda Gates Foundation to make fast the manufacturing and delivery of up to 100 million doses for these 92 countries under LMIC.
Also, up to 50 million doses are decided to be made available in India alone the other 50 million would be distributed amongst the other 91 countries, according to the sources they are close.
Except for this, India is expected to get up to a half-billion doses from AstraZeneca, and some part of the one billion doses by Novavax, this is a part of their agreement to Serum Institute.
By this partnership, the company can accelerate manufacturing and delivery of up to 100 million doses as part of this agreement for India and LMICs, till the first half of 2021, CEO- Adar Poonawalla, Serum Institute said.
This collaboration will provide capital to Serum to increase their manufacturing capacity, so that once a vaccine gains approval and WHO prequalifications, doses can be produced at a large scale for distribution to the INDIA and LMICs. Expectation vaccine would arrive in the first half of the 2021 Doses are expected to be distributed on a proportional basis amongst 92 countries.
The WHO global allocation framework will design the distribution idea for the vaccine. It is decided that priority would be high for healthcare professionals and frontline persons and essential workers, in addition to those most at risk from the virus such as people with bad health conditions.
The time would depend upon the result of the phase 3 trials, and approval of the Drug control General of INDIA and after qualifying the WHO prequalifications, the vaccine is expected to arrive in the first half of 2020, if everything goes well.
Decisions for investment in manufacturing are taking place in collaboration between these 3 organizations. Hope, this COVID makes a fast relief, be safe, and use sanitizer often, wear your mask whenever you are exposed to the external environment. You are precious readers, we want you to be safe. Subscribe our notifications and join the community by following on other handles of ours.